07:00 , Oct 3, 2013 |  BC Innovations  |  Cover Story

Escaping abiraterone

Although numerous papers have detailed how castration-resistant prostate cancers become refractory to Xtandi enzalutamide and other second-generation androgen receptor antagonists, comparatively little is known about how the disease eventually evades CYP17 inhibitors such as Zytiga...
07:00 , Sep 26, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Hydroxysteroid 3b dehydrogenase 1 (HSD3B1) In vitro and mouse studies...